Supernus Pharmaceuticals(SUPN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Supernus achieved record total revenues of $719 million for the full year 2025, representing a 27% increase compared to the previous year [17] - The fourth quarter of 2025 saw total revenue of $211.6 million, a 21% increase year-over-year, with net product sales of $158.1 million [13] - GAAP net loss for the full year 2025 was $38.6 million, or a loss of $0.68 per diluted share, compared to a GAAP net earnings of $73.9 million, or $1.32 per diluted share in 2024 [18] Business Line Data and Key Metrics Changes - Revenues from the four growth products (Qelbree, Proquarius, Zerzura, and ONAPGO) accounted for approximately 76% of total revenues in Q4 2025 [4] - ONAPGO generated net sales of $8.9 million in Q4 2025, up from $6.8 million in Q3 2025, with total net sales of $17.3 million for its first year [5] - Zurzuvae had collaboration revenues of $32.8 million in Q4 2025, with U.S. sales increasing approximately 187% compared to the same period in 2024 [7] - Qelbree exceeded $300 million in net sales for 2025, delivering 26% growth compared to 2024 [8] Market Data and Key Metrics Changes - The number of prescribers for ONAPGO grew by 28% in Q4 2025 compared to Q3 2025, with prescriptions increasing by 29.6% [6] - The number of prescribers for Zurzuvae doubled in 2025 compared to 2024, with total prescriptions increasing by more than 150% [8] Company Strategy and Development Direction - The company successfully executed an integrated acquisition of Sage Therapeutics and obtained FDA approval for ONAPGO, launching it in the Parkinson's market [4] - Corporate development remains a top priority, with a focus on additional strategic opportunities to strengthen future growth in CNS through revenue-generating products or late-stage pipeline candidates [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to meet demand for ONAPGO through existing suppliers and anticipated a smooth transition to a second supplier in 2027 [23][50] - The company expects total revenues for 2026 to range from $840 million to $870 million, with guidance assuming $45 million to $70 million in net sales from ONAPGO [20] Other Important Information - Combined R&D and SG&A expenses for 2025 were $591.8 million, up from $430.4 million in 2024, primarily due to acquisition-related costs [18] - The company had approximately $309 million in cash equivalents and marketable securities as of December 31, 2025, down from $454 million the previous year [19] Q&A Session Summary Question: ONAPGO supply and sales potential - Management confirmed that the current supplier can meet the $45 million-$70 million sales guidance for ONAPGO, with plans for continuity of supply into 2027 [23] Question: ONAPGO demand and backlog clearance - Management indicated that the current supplier will help clear the backlog and meet ongoing demand throughout 2026 [29] Question: R&D prioritization post-Sage acquisition - Management stated that early-stage assets will undergo preclinical work, and prioritization will be based on market opportunity and ROI [30] Question: Gross-to-net expectations for ONAPGO - Management expects gross-to-net for ONAPGO to be in the range of 20%-30%, typically higher in Q1 [66]